CatalystWireBeta

Share Buyback

In brief · summary, not quotable

EKF Diagnostics Holdings plc has concluded its share buyback programme by purchasing 104,720 ordinary shares at a weighted average price of 24.98p per share, with these shares to be cancelled. The overall buyback programme, announced on 21 May 2025 and extended on 2 February 2026, resulted in the acquisition of 21,125,398 ordinary shares at a weighted average price of 25.93p. Following the cancellation, EKF's total issued share capital will be 427,968,392 ordinary shares, with no shares held in treasury, meaning the total number of voting rights will be 427,968,392.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your EKF notes

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that it has purchased a total of 104,720 of its ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) at a weighted average price of 24.98p pence per share. The purchased shares will be cancelled.

This transaction marks the successful conclusion of the share buyback programme announced on 21 May 2025 and extended on 2 February 2026. Pursuant to the share buyback programme, a total of 21,125,398 ordinary shares have been purchased at a weighted average price of 25.93p per Ordinary Share.

Aggregated information

Date of purchase28 September 2026
Number of Ordinary Shares purchased104,720
Highest price paid per Ordinary Share25.00p
Lowest price paid per Ordinary Share24.90p
Volume weighted average price paid24.98p
Transaction details
Number of Ordinary Shares purchasedTransaction price (GBp)Time of transactionTrading venue
40,00025.0p16:03:06AIMX
40,00025.0p16:06:13AIMX
24,66224.9p16:29:10AIMX
5824.9p16:34:25AIMX

Total voting rights

Following the purchase and after the cancellation of the shares becomes effective, the Company's total issued share capital will consist of 427,968,392 Ordinary Shares. There are no shares held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 427,968,392. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The person responsible for arranging the release of this Announcement

on behalf of the Company is Julian Baines, Executive Chair.

EKF Diagnostics Holdings plcwww.ekfdiagnostics.com
Julian Baines, Executive Chairvia Walbrook PR
Gavin Jones, Chief Executive Officer
Singer Capital Markets (Nominated Adviser & Broker)Tel: +44 (0)20 7496 3000
Jen Boorer / Russell Cook / Patrick Weaver
Walbrook PR LimitedTel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Alice WoodingsMob: +44 (0)7980 541 893 / +44 (0) 7407 804 654

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note